Skip to content

Postoperative Pain Management Following Laparoscopic Cholecystectomy

Postoperative Pain Management Following Laparoscopic Cholecystectomy- Vortioxetine

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06561438
Enrollment
86
Registered
2024-08-20
Start date
2024-08-06
Completion date
2025-06-07
Last updated
2025-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

laparoscopic, 5-HT3 and 5-HT7 receptors inhibition, post-operative pain

Brief summary

Postoperative pain management is essential and the inability to treat acute pain appropriately in the first 48 postoperative hours represents a risk factor for developing chronic pain. No. study has investigated Vortioxetine as an adjuvant to standard care for postoperative pain management in patients undergoing LC

Detailed description

Postoperative pain is a main challenge for delayed hospital discharge in Laparoscopic cholecystectomy. . Postoperative pain management is essential and the inability to treat acute pain appropriately in the first 48 postoperative hours represents a risk factor for developing chronic pain. Vortioxetine (VO) is a multimodal serotonergic antidepressant with a unique mechanism of action that is effective in treating neuropathic pain. The purpose of this study is evaluating the efficacy and tolerability of preoperative oral administration of Vortioxetine on postoperative pain control in patients undergoing LC

Interventions

20 mg oral vortioxetine tablet 2 hours before the procedure

Sponsors

Future University in Egypt
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients who are scheduled to undergo elective LC. * Adults (males and/or females) between the ages of 18-70 years old.

Exclusion criteria

* Chronic pain other than cholelithiasis. * Patients who received analgesics or sedatives 24 h before scheduled surgery. * Severe hepatic (Child Pugh Class B and C) and renal dysfunction (CrCl \<30ml/min) * Previous allergic response to vortioxetine. * Pregnancy and lactation * Patients with communication problems, cognitive dysfunction, or psychological disorders * Daily corticosteroid use

Design outcomes

Primary

MeasureTime frameDescription
VAS score (Visual analogue scale)2 hours, 4 hours, 8 hours, 12 hours, 24 hoursPain intensity: VAS score from 0 to 100 mm In which 0 means no pain, and 100 means the worst pain possible

Secondary

MeasureTime frameDescription
Time to analgesic request24 hoursTime to analgesic request
Quality of life (QoL) after laparoscopic cholecystectomy (LC)3 monthsGastrointestinal Quality of Life Index questionnaire for QOL assessment with calculation of the score; most desirable option: 4 points, least desirable option: 0 points and GIQLI score: sum of the point. GIQLI ranges from 0 to 80 with higher scores indicating a better quality of life.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026